Marubi(SH:603983) Xin Lang Zheng Quan·2025-10-13 03:39Core Insights - Marubi Biotech's stock price decreased by 2.01% on October 13, trading at 37.98 CNY per share with a market capitalization of 15.23 billion CNY [1] - The company has seen a year-to-date stock price increase of 19.58%, but has experienced declines of 3.33% over the last five trading days, 7.41% over the last 20 days, and 7.03% over the last 60 days [1] - Marubi Biotech's revenue for the first half of 2025 reached 1.769 billion CNY, representing a year-on-year growth of 30.83%, while net profit attributable to shareholders was 186 million CNY, up 5.21% year-on-year [2] Financial Performance - The company has distributed a total of 983 million CNY in dividends since its A-share listing, with 610 million CNY distributed over the past three years [3] - As of June 30, 2025, the number of shareholders increased by 36.85% to 17,400, while the average number of circulating shares per person decreased by 26.93% to 23,084 shares [2] Shareholder Structure - The fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 4.85 million shares, an increase of 1.49 million shares from the previous period [3] - Several funds, including 富国消费主题混合A and 富国价值创造混合A, have seen changes in their holdings, with some increasing and others decreasing their share counts [3] Business Overview - Marubi Biotech, established on April 2, 2002, specializes in the research, design, production, and sales of various skincare products, with a revenue composition of 39.20% from skincare, 29.30% from beauty and other categories, 23.75% from eye care, and 7.66% from cleansing products [1]